Athersys, Inc. (ATHX) financial statements (2021 and earlier)

Company profile

Business Address 3201 CARNEGIE AVENUE
CLEVELAND, OH 44115-2634
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments52355129152326
Cash and cash equivalents52355129152326
Receivables  01101
Other undisclosed current assets3271100
Total current assets:55375831162427
Noncurrent Assets
Operating lease, right-of-use asset1 
Property, plant and equipment3332311
Other noncurrent assets   0   
Other undisclosed noncurrent assets121 000
Total noncurrent assets:5442311
TOTAL ASSETS:60426234192529
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31126644
Accounts payable  94533
Accrued liabilities1100111
Employee-related liabilities2121111
Debt     0 
Deferred revenue and credits1 00
Other undisclosed current liabilities201143000
Total current liabilities:23131510755
Noncurrent Liabilities
Long-term debt and lease obligation      0
Long-term debt, excluding current maturities      0
Liabilities, other than long-term debt00 0   
Customer advances or deposits0   
Other liabilities00     
Total noncurrent liabilities:00 0  0
Total liabilities:23131510755
Stockholders' equity
Stockholders' equity attributable to parent, including:31234323112021
Common stock0000000
Additional paid in capital528441416374329323307
Accumulated deficit(496)(418)(373)(351)(318)(303)(287)
Warrants and rights outstanding      3
Other undisclosed stockholders' equity attributable to parent      (3)
Total stockholders' equity:31234323112021
Other undisclosed liabilities and equity553 113
TOTAL LIABILITIES AND EQUITY:60426234192529

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues1624417122
Revenue, net417122
Cost of revenue(1)    (0)(0)
Gross profit:1624417121
Operating expenses(79)(50)(48)(36)(32)(29)(30)
Other undisclosed operating loss (1)(1)(1)(0)  
Operating loss:(78)(45)(25)(33)(15)(17)(29)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)1100(0)0
Loss from continuing operations before equity method investments, income taxes:(79)(45)(24)(33)(15)(17)(29)
Other undisclosed income (loss) from continuing operations before income taxes   1(1)17
Loss from continuing operations before income taxes:(79)(45)(24)(32)(15)(16)(22)
Income tax benefit    000
Net loss available to common stockholders, basic:(79)(45)(24)(32)(15)(16)(22)
Dilutive securities, effect on basic earnings per share      (2)
Other undisclosed net loss available to common stockholders, diluted     (0) 
Net loss available to common stockholders, diluted:(79)(45)(24)(32)(15)(17)(24)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(79)(45)(24)(32)(15)(16)(22)
Comprehensive loss, net of tax, attributable to parent:(79)(45)(24)(32)(15)(16)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: